Page last updated: 2024-11-03

riluzole and Tourette Syndrome

riluzole has been researched along with Tourette Syndrome in 2 studies

Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.

Tourette Syndrome: A neuropsychological disorder related to alterations in DOPAMINE metabolism and neurotransmission involving frontal-subcortical neuronal circuits. Both multiple motor and one or more vocal tics need to be present with TICS occurring many times a day, nearly daily, over a period of more than one year. The onset is before age 18 and the disturbance is not due to direct physiological effects of a substance or another medical condition. The disturbance causes marked distress or significant impairment in social, occupational, or other important areas of functioning. (From DSM-IV, 1994; Neurol Clin 1997 May;15(2):357-79)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lemmon, ME1
Grados, M2
Kline, T1
Thompson, CB1
Ali, SF1
Singer, HS2
Morris, C1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Combined PET and MR Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 1: Simultaneous PET and 3T MRI[NCT05232955]40 participants (Anticipated)Observational2022-02-28Not yet recruiting
Combined PET and MR Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 2: 7T MRI[NCT05233306]60 participants (Anticipated)Observational2022-01-27Recruiting
Double-Blind, Placebo-Controlled Trial of N-acetylcysteine (NAC) for the Treatment of Children With Tourette Syndrome[NCT01172288]Phase 231 participants (Actual)Interventional2010-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Improvement in OCD Severity

Childrens' Yale-Brown Obsessive-Compulsive Scale (CY-BOCS). 10-item scale. Each item is rated from 0-4. A sum total is calculated by adding items 1-10. 0-7: Subclinical. 8-15: Mild. 16-23: Moderate. 24-31: Severe. 32-40: Extreme. (NCT01172288)
Timeframe: 12 weeks

Interventionunits on a scale (Mean)
N-Acetylcysteine4.4
Placebo11.5

Improvement in Tic Severity

"Yale Global Tic Severity Scale is a standard psychiatric measure that rates tics from 0 (no tics) to 100 (most severe tics).~It separately rates motor tics and vocal tics in 5 subscales (number, frequency, intensity, complexity and interference) where the maximum severity score for motor tics is 25 and for vocal tics is 25. Giving us the Total Tic Severity Score maximum of 50.~The additional Impairment Scale rates the degree of disability caused by the tics ranging from 0 (none) to 50 (severe). When these two scores are added we get the Yale Global Tic Severity Scale Score." (NCT01172288)
Timeframe: 12 weeks

Interventionunits on a scale (Mean)
N-Acetylcysteine24.3
Placebo21.3

Improvement of Premonitory Urges

"Premonitory Urge for Tics Scale (PUTS). Items are rated on a scale of 1-4 from least to most. A total score is calculated by summing the scores of all items. Nine is the minimum possible score. A score of 12.5-24.5 indicates medium intensity of premonitory urges for tics. A score of 25-30.5 indicates high intensity which may be associated with marked impairment. Scores 31 and above indicate extremely high intensity with probable severe impairment. A score of 36 is the maximum score possible." (NCT01172288)
Timeframe: 12 weeks

Interventionunits on a scale (Mean)
N-Acetylcysteine24.7
Placebo24.1

Overall Improvement

Clinical Global Impression - Improvement Scale (CGI-I). The CGI is a 7-point scare that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. 1 = Very much improved; 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 = Minimally worse; 6 = Much worse; 7 = Very much worse. (NCT01172288)
Timeframe: 12 weeks

Interventionunits on a scale (Mean)
N-Acetylcysteine3.3
Placebo3.4

Number of Participants With Adverse Effects

Number of participants with adverse events according to the Pediatric Adverse Events Rating Scale (NCT01172288)
Timeframe: 12 weeks

,
Interventionparticipants (Number)
IrritabilitySadness or depressed moodFatigueInsomniaDecreased appetiteChest painSyncopeStomach acheNauseaVomitingHeadache
N-Acetylcysteine00000000001
Placebo01000002301

Trials

1 trial available for riluzole and Tourette Syndrome

ArticleYear
Efficacy of Glutamate Modulators in Tic Suppression: A Double-Blind, Randomized Control Trial of D-serine and Riluzole in Tourette Syndrome.
    Pediatric neurology, 2015, Volume: 52, Issue:6

    Topics: Adolescent; Child; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Humans; Male; Ril

2015

Other Studies

1 other study available for riluzole and Tourette Syndrome

ArticleYear
Glutamatergic modulatory therapy for Tourette syndrome.
    Medical hypotheses, 2010, Volume: 74, Issue:5

    Topics: Cycloserine; Dopamine; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glutamic A

2010
Glutamatergic modulatory therapy for Tourette syndrome.
    Medical hypotheses, 2010, Volume: 74, Issue:5

    Topics: Cycloserine; Dopamine; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glutamic A

2010
Glutamatergic modulatory therapy for Tourette syndrome.
    Medical hypotheses, 2010, Volume: 74, Issue:5

    Topics: Cycloserine; Dopamine; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glutamic A

2010
Glutamatergic modulatory therapy for Tourette syndrome.
    Medical hypotheses, 2010, Volume: 74, Issue:5

    Topics: Cycloserine; Dopamine; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glutamic A

2010
Glutamatergic modulatory therapy for Tourette syndrome.
    Medical hypotheses, 2010, Volume: 74, Issue:5

    Topics: Cycloserine; Dopamine; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glutamic A

2010
Glutamatergic modulatory therapy for Tourette syndrome.
    Medical hypotheses, 2010, Volume: 74, Issue:5

    Topics: Cycloserine; Dopamine; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glutamic A

2010
Glutamatergic modulatory therapy for Tourette syndrome.
    Medical hypotheses, 2010, Volume: 74, Issue:5

    Topics: Cycloserine; Dopamine; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glutamic A

2010
Glutamatergic modulatory therapy for Tourette syndrome.
    Medical hypotheses, 2010, Volume: 74, Issue:5

    Topics: Cycloserine; Dopamine; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glutamic A

2010
Glutamatergic modulatory therapy for Tourette syndrome.
    Medical hypotheses, 2010, Volume: 74, Issue:5

    Topics: Cycloserine; Dopamine; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glutamic A

2010